Facebook Instagram Twitter Linkedin Youtube

Duchenne News Tags: Entrada Therapeutics

Search
Tags
Tags
Antisense Therapeutics Astellas Avidity Biosciences Dyne Edgewise Entrada Therapeutics Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Solid Biosciences Wave Life Sciences
January 10, 2023

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne who are Exon 45 Skipping Amenable

Entrada announces the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45
Read More
December 21, 2022

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada announces clinical hold notice from U.S. FDA regarding IND for ENTR-601-44
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Experience the magic of camp promise

    Complete applications due April 3, 2023.
    Apply Now